| Margins | EBITDA margin impacted by product mix and lower animal nutrition realizations. |
|---|---|
| Demand visibility | Strong domestic demand; India reached 47% of revenue. |
| Management confidence | High on structural direction and human nutrition growth. |
Growth
Revenue down 13% YoY; PAT down 56% YoY due to exceptionally strong FY26 base with non-recurring income.
Outlook
Investing INR 110 crore in Dahej for Calcifediol; targeting plant-source D3 leadership and expanding into EU/USA markets.
Risks
Animal nutrition volumes fell 52% QoQ/20% YoY; realization down 40% YoY on weak global pricing.
Investor Presentation filed with BSE, NSE: FERMENTA. Summary written with AI assistance from the document.
Fermenta Biotech Ltd: key numbers
- Share price
- ₹468.15
- Market cap
- ₹1,378 Cr
- Revenue (annual)
- ₹525.4 Cr
- Net profit (annual)
- ₹71.77 Cr
- P/E (TTM)
- 22.8×Sector 50.4×
- Promoter holding
- 64.09%+0.00% QoQ
- FII holding
- 0.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fermenta Biotech Ltd
All →Fermenta Biotech Other Announcement
KMP Sumesh Gandhi sold a total of 3,900 equity shares in three separate market transactions on September 7, 8, and 9, 2026.
- Value
- ₹0.20 Cr
Fermenta Biotech Partnership
Fermenta Biotech Limited signed an exclusive licence agreement with VIT Vellore to commercialize Vitamin B12 fortification technology for fermented foods, enhancing its product portfolio.
- From
- Vellore Institute of Technology (VIT), Vellore
Fermenta Biotech Promoter Selling: ₹2.2 Cr
Director Prashant Nagre sold 44,000 shares of Fermenta Biotech Ltd via market sale. The transaction value is Rs.2.20 Crore.
- Value
- ₹2.20 Cr
- Promoter stake change
- -0.15%
Fermenta Biotech Q1 FY27 Results: Net Profit ₹9.5 Cr, Down 56.0% YoY
Fermenta Biotech Ltd reported revenue from operations of ₹121.8 Cr (-10.6% YoY) and net profit of ₹9.5 Cr (-56.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹9.5 Cr · -56.0% YoY
Fermenta Biotech Earnings Call: Key Takeaways
Fermenta Biotech delivered core revenue growth of 27% YoY in FY26, driven by Vitamin D3 segments, despite headline declines from a high real-estate base in FY25.
Fermenta Biotech Q4 FY26 Results: Net Profit ₹18.6 Cr, Down 44.1% YoY
Fermenta Biotech Ltd reported revenue from operations of ₹121.6 Cr (-13.0% YoY) and net profit of ₹18.6 Cr (-44.1% YoY) for Q4 FY26.
- Key figure
- Net profit ₹18.6 Cr · -44.1% YoY